Abstract
Sarcomas are the mesenchymal-derived malignant tumors of connective tissues (e.g., fat, bone, and cartilage) presumed to arise from aberrant development or differentiation of mesenchymal stem cells (MSCs). Appropriate control of stem cell maintenance versus differentiation allows for normal connective tissue development. Current theories suggest that loss of this control-through accumulation of genetic lesions in MSCs at various points in the differentiation process -leads to development of sarcomas, including undifferentiated, high grade sarcoma tumors [1]. The initiation of stem cell differentiation is highly associated with alteration of gene expression, which depends on chromatin remodeling [2, 3]. Epigenetic chromatin modifying agents have been shown to induce cancer cell differentiation and are currently being used clinically to treat cancer. This review will focus on the importance of epigenetic chromatin remodeling in the context of mesenchymal stem cells, sarcoma tumorigenesis and differentiation therapy.
Keywords: Mesenchymal stem cell, sarcoma, differentiation, histone deacetylase inhibitor, chromatin
Current Stem Cell Research & Therapy
Title: Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Volume: 5 Issue: 1
Author(s): Sara Siddiqi, Joslyn Mills and Igor Matushansky
Affiliation:
Keywords: Mesenchymal stem cell, sarcoma, differentiation, histone deacetylase inhibitor, chromatin
Abstract: Sarcomas are the mesenchymal-derived malignant tumors of connective tissues (e.g., fat, bone, and cartilage) presumed to arise from aberrant development or differentiation of mesenchymal stem cells (MSCs). Appropriate control of stem cell maintenance versus differentiation allows for normal connective tissue development. Current theories suggest that loss of this control-through accumulation of genetic lesions in MSCs at various points in the differentiation process -leads to development of sarcomas, including undifferentiated, high grade sarcoma tumors [1]. The initiation of stem cell differentiation is highly associated with alteration of gene expression, which depends on chromatin remodeling [2, 3]. Epigenetic chromatin modifying agents have been shown to induce cancer cell differentiation and are currently being used clinically to treat cancer. This review will focus on the importance of epigenetic chromatin remodeling in the context of mesenchymal stem cells, sarcoma tumorigenesis and differentiation therapy.
Export Options
About this article
Cite this article as:
Siddiqi Sara, Mills Joslyn and Matushansky Igor, Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas, Current Stem Cell Research & Therapy 2010; 5 (1) . https://dx.doi.org/10.2174/157488810790442859
DOI https://dx.doi.org/10.2174/157488810790442859 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection
Current Pharmaceutical Design Advances of Phenoxazines: Synthesis, Reactivity and Their Medicinal Applications
Current Medicinal Chemistry Designing and Formulation Optimization of Hyaluronic Acid Conjugated PLGA Nanoparticles of Tamoxifen for Tumor Targeting
Pharmaceutical Nanotechnology CD40L - A Multipotent Molecule for Tumor Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets State of Research Tracks and Property Protection of Photodynamic Sensitizers and Delivery Methodologies
Recent Patents on Chemical Engineering PEGylated Liposomal Vancomycin: A Glimmer of Hope for Improving Treatment Outcomes in MRSA Pneumonia
Recent Patents on Anti-Infective Drug Discovery Development of Ribonucleotide Reductase Inhibitors: A Review on Structure Activity Relationships
Mini-Reviews in Medicinal Chemistry Protein Kinase C as a Drug Target Implications for Drug or Diet Prevention and Treatment of Cancer
Current Drug Targets The Role of Iron Chelation in Cancer Therapy
Current Medicinal Chemistry Transductional Targeting with Recombinant Adenovirus Vectors
Current Gene Therapy When BMP Signalling Goes Wrong: The Intracellular and Molecular Mechanisms of BMP Signalling in Cancer
Current Signal Transduction Therapy Modulating Mitochondria-Mediated Apoptotic Cell Death through Targeting of Bcl-2 Family Proteins
Recent Patents on DNA & Gene Sequences The Synergistic Effect of Humanized Monoclonal Antibodies Targeting Insulin-Like Growth Factor 1 Receptor (IGF-1R) and Chemotherapy
Current Drug Targets Telomeres, Telomerase and Malignant Transformation
Current Molecular Medicine VEGF Inhibitors in Cancer Therapy
Current Pharmaceutical Design Targeting Angiogenesis in Renal Cell Carcinoma
Current Cancer Drug Targets Bioengineering RNA Silencing Across the Life Kingdoms
Recent Patents on Biotechnology Meet Our Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers
Current Medicinal Chemistry Potassium Channels are a New Target Field in Anticancer Drug Design
Recent Patents on Anti-Cancer Drug Discovery